# A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

> **NCT04495933** · PHASE1 · COMPLETED · sponsor: **The University of Queensland** · enrollment: 216 (actual)

## Conditions studied

- SARS-CoV2
- Covid19

## Interventions

- **BIOLOGICAL:** MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
- **BIOLOGICAL:** MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
- **BIOLOGICAL:** MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04495933
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-13
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2024-05-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495933, "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04495933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*